The global glioblastoma multiforme treatment market size was estimated at USD 4.04 billion in 2025 and is projected to reach USD 7.87 billion by 2033, growing at a CAGR of 8.69% from 2026 to 2033. The rising prevalence of Glioblastoma Multiforme (GBM) and its significant clinical burden are critical drivers in the GBM treatment industry.
The expanding evidence base has reinforced temozolomide’s (TMZ) role as a cornerstone in glioblastoma multiforme (GBM) treatment. Several recent real-world studies and meta-analyses have shown that continuing TMZ therapy beyond the standard six cycles may provide additional survival benefits, particularly in patients with favorable molecular features such as MGMT promoter methylation or low Ki-67 expression. A meta-analysis published in Neuro-Oncology Advances in July 2023 reviewed outcomes from 2,578 patients across 16 nonrandomized studies and 5 randomized controlled trials. The analysis found that extended therapy was linked to a 28% reduction in disease progression and a 29% decrease in mortality risk, though most of these benefits were observed in retrospective cohorts. These findings highlight the need for further randomized investigations to establish the definitive value of prolonged adjuvant use. In addition, ongoing trials are evaluating TMZ in combination with immunotherapies and tumor-treating fields, supported by its tolerability and consistent clinical performance.
Cost-effectiveness and broad availability have also contributed to the widespread uptake of TMZ worldwide. The introduction of generic formulations has reduced treatment expenses, improving access without compromising therapeutic outcomes. Its favorable safety profile and established efficacy make it a preferred choice across diverse healthcare systems. A Phase IIa trial, published in March 2023 in the Journal of Clinical Oncology, assessed the SurVaxM vaccine alongside adjuvant TMZ in newly diagnosed GBM patients. Results demonstrated a median progression-free survival of 11.4 months and an overall survival of 25.9 months, with robust immune responses and no severe vaccine-related side effects, underscoring the potential of combination approaches. As emerging therapies evolve, many continue to build on TMZ as a foundation, reinforcing its critical role in the standard management of GBM.
The global uptake of tumor treating fields (TTF) continues to accelerate, supported by broader access and favorable reimbursement policies. Many healthcare systems have included TTF among reimbursable treatment options, reducing financial hurdles for patients who qualify. By late 2024, Novocure reported more than 4,000 patients worldwide actively using its Optune Gio TTF system, with strong adoption in regions such as the United States, Germany, France, and Japan. This rising user base reflects growing physician confidence and patient acceptance of the therapy across both advanced and emerging healthcare settings. The positive outcomes are also driving innovation, with ongoing efforts focused on technological upgrades and expanding its use in other tumor types. Collectively, these developments are positioning TTF as an integral element in the evolving management of glioblastoma multiforme.
The five-year survival data shows a marked difference between treatment approaches, with radiation therapy (RT) alone resulting in a 16.2% survival rate compared to 83.8% when combined with temozolomide (TMZ). This demonstrates the significant clinical advantage of multimodal therapy, particularly TMZ’s role in enhancing outcomes for GBM patients. Such findings validate the continued reliance on TMZ as the backbone of GBM therapy and reinforce the demand for chemotherapy drugs in combination protocols. The evidence also supports healthcare providers’ preference for integrated treatment approaches, strengthening the adoption of combination therapies in clinical practice.
From a market perspective, this survival benefit will continue to drive investment in combination regimens and fuel demand for supportive therapeutics like TMZ. Pharmaceutical companies are expected to leverage these outcomes by developing next-generation therapies that complement or enhance TMZ’s effects, including immunotherapies and targeted agents. The higher survival outcomes with RT+TMZ will influence treatment guidelines, leading to broader reimbursement coverage and increased uptake across hospitals and cancer centers. This shift will not only sustain the dominance of TMZ in the GBM treatment market but also create opportunities for novel adjunctive therapies positioned alongside it.
The expanding evidence base has reinforced temozolomide’s (TMZ) role as a cornerstone in glioblastoma multiforme (GBM) treatment. Several recent real-world studies and meta-analyses have shown that continuing TMZ therapy beyond the standard six cycles may provide additional survival benefits, particularly in patients with favorable molecular features such as MGMT promoter methylation or low Ki-67 expression. A meta-analysis published in Neuro-Oncology Advances in July 2023 reviewed outcomes from 2,578 patients across 16 nonrandomized studies and 5 randomized controlled trials. The analysis found that extended therapy was linked to a 28% reduction in disease progression and a 29% decrease in mortality risk, though most of these benefits were observed in retrospective cohorts. These findings highlight the need for further randomized investigations to establish the definitive value of prolonged adjuvant use. In addition, ongoing trials are evaluating TMZ in combination with immunotherapies and tumor-treating fields, supported by its tolerability and consistent clinical performance.
Cost-effectiveness and broad availability have also contributed to the widespread uptake of TMZ worldwide. The introduction of generic formulations has reduced treatment expenses, improving access without compromising therapeutic outcomes. Its favorable safety profile and established efficacy make it a preferred choice across diverse healthcare systems. A Phase IIa trial, published in March 2023 in the Journal of Clinical Oncology, assessed the SurVaxM vaccine alongside adjuvant TMZ in newly diagnosed GBM patients. Results demonstrated a median progression-free survival of 11.4 months and an overall survival of 25.9 months, with robust immune responses and no severe vaccine-related side effects, underscoring the potential of combination approaches. As emerging therapies evolve, many continue to build on TMZ as a foundation, reinforcing its critical role in the standard management of GBM.
The global uptake of tumor treating fields (TTF) continues to accelerate, supported by broader access and favorable reimbursement policies. Many healthcare systems have included TTF among reimbursable treatment options, reducing financial hurdles for patients who qualify. By late 2024, Novocure reported more than 4,000 patients worldwide actively using its Optune Gio TTF system, with strong adoption in regions such as the United States, Germany, France, and Japan. This rising user base reflects growing physician confidence and patient acceptance of the therapy across both advanced and emerging healthcare settings. The positive outcomes are also driving innovation, with ongoing efforts focused on technological upgrades and expanding its use in other tumor types. Collectively, these developments are positioning TTF as an integral element in the evolving management of glioblastoma multiforme.
The five-year survival data shows a marked difference between treatment approaches, with radiation therapy (RT) alone resulting in a 16.2% survival rate compared to 83.8% when combined with temozolomide (TMZ). This demonstrates the significant clinical advantage of multimodal therapy, particularly TMZ’s role in enhancing outcomes for GBM patients. Such findings validate the continued reliance on TMZ as the backbone of GBM therapy and reinforce the demand for chemotherapy drugs in combination protocols. The evidence also supports healthcare providers’ preference for integrated treatment approaches, strengthening the adoption of combination therapies in clinical practice.
From a market perspective, this survival benefit will continue to drive investment in combination regimens and fuel demand for supportive therapeutics like TMZ. Pharmaceutical companies are expected to leverage these outcomes by developing next-generation therapies that complement or enhance TMZ’s effects, including immunotherapies and targeted agents. The higher survival outcomes with RT+TMZ will influence treatment guidelines, leading to broader reimbursement coverage and increased uptake across hospitals and cancer centers. This shift will not only sustain the dominance of TMZ in the GBM treatment market but also create opportunities for novel adjunctive therapies positioned alongside it.
Global Glioblastoma Multiforme Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global glioblastoma multiforme treatment market report based on treatment, end use, and region:Treatment Outlook (Revenue, USD Million, 2021-2033)
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy (Bevacizumab)
- Tumor Treating Field (TTF) Therapy
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Clinics / Outpatient Centers
- Ambulatory Surgical Centers
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends, & Scope
Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Business Analysis
Chapter 5. Glioblastoma Multiforme Treatment Market: End Use Business Analysis
Chapter 6. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Glioblastoma Multiforme Treatment market report include:- Merck & Co., Inc.
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Arbor Pharmaceuticals, LLC
- Amneal Pharmaceuticals
- Karyopharm Therapeutics, Inc.
- Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | January 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 4.04 Billion |
| Forecasted Market Value ( USD | $ 7.87 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
